RadNet Acquires CIMAR UK, Empowering DeepHealth to Accelerate AI-Powered Imaging, Reporting and Image-Based Screening

Rhea-AI Summary

RadNet (NASDAQ: RDNT) announced the acquisition of CIMAR UK on November 11, 2025, integrating CIMAR into RadNet’s DeepHealth digital health unit to advance AI-powered, connected imaging-based care across the UK and Europe.

CIMAR provides cloud-native image management across >50% of NHS trusts and 80% of UK private hospital groups; an existing DeepHealth–CIMAR partnership already connects DeepHealth’s AI lung solution to >90% of NHS Lung Cancer Screening Program sites. UK data show a shift to earlier detection (76% detected at earlier stages vs 29% historically).

Positive

• CIMAR coverage across >50% NHS trusts and 80% UK private groups
• DeepHealth integration expands end-to-end AI informatics and workflow capabilities
• Lung screening impact: 76% early-stage detection vs 29% historical

Negative

• None.

Insights

Digital Health Strategist

RadNet's acquisition of CIMAR strengthens DeepHealth's cloud-native imaging infrastructure and expands UK reach, likely positive for scaling AI-enabled screening.

RadNet will integrate CIMAR into DeepHealth to combine CIMAR’s cloud-native image-management infrastructure with DeepHealth’s AI-powered informatics and population-health applications, creating a connected stack for imaging, reporting and image-based screening. CIMAR already connects across more than 50% of NHS Trusts and 80% of UK private hospital groups and supports over 90% of the NHS England Lung Cancer Screening Program sites, which the announcement links to a shift from 29% historically to 76% of cancers detected at earlier stages.

The transaction’s business mechanism is consolidation of infrastructure and AI in a single operational platform to reduce fragmentation and enable wider deployment of AI screening and reporting at scale; this could materially increase reach for DeepHealth’s tools. Key dependencies include successful technical and operational integration, maintenance of existing NHS and private deployments, and continued performance of the screening workflows already in place. Watch integration milestones and any reported metrics on screening coverage and stage-shift outcomes after the acquisition announcement on Nov 11, 2025, as these will indicate whether the combined platform delivers the claimed scale and clinical impact within the UK and potential expansion into Europe.

Acquisition supplements CIMAR’s cloud-native infrastructure with DeepHealth’s AI-powered informatics to deliver connected, efficient and accessible care

LOS ANGELES and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a US leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today the acquisition of CIMAR UK, a leading provider of cloud-native healthcare image management solutions. CIMAR will be integrated into DeepHealth, RadNet’s wholly owned subsidiary and a global leader in AI-powered health informatics, to advance connected imaging-based care.

“Imaging and diagnostics sit at the forefront of care, serving as the gateway to treatment and disease management,” said Kees Wesdorp, CEO and President of RadNet’s Digital Health division, DeepHealth. “Radiologists and care teams are under immense pressure, often working with outdated or siloed tools, and are not set-up to keep pace with rising demand. By acquiring CIMAR, DeepHealth is taking a powerful step in redefining imaging-based care through a portfolio of solutions that connect clinical and operational intelligence to enable faster, more accurate diagnoses and improve efficiency.”

CIMAR deploys an extensive image management infrastructure that provides data connectivity and interoperability to enable vendor-neutral solutions, such as clinical AI, across more than 50% of National Health Service Trusts and 80% of UK private hospital groups. As imaging volumes continue to rise and fragmented technologies create barriers to efficient, coordinated care, CIMAR’s model of a centralized image infrastructure has demonstrated its capability to deliver connected healthcare.

The acquisition combines complementary capabilities, CIMAR’s cloud-native infrastructure and services—which enhance data connectivity and interoperability across public and private healthcare systems in the UK—with DeepHealth’s leading end-to-end informatics and population health applications, from patient engagement tools and AI-based reporting to viewing and workflow applications. Together, they can create a richer solution for advancing efficient, coordinated and accessible imaging-based care across the UK.

“This acquisition marks a pivotal moment for CIMAR,” said Howard Jenkinson, Co-Founder and Chief Executive Officer of CIMAR. “Through our integration with DeepHealth, we can scale our impact and expand access to services and solutions that provide a more seamless, connected, and intelligent imaging experience. Together, we aim to empower healthcare providers with the tools they need to stay at the forefront of medical imaging innovation, supporting them in delivering the highest standard of care.”

Today, an existing partnership between DeepHealth and CIMAR underpins the NHS England’s Lung Cancer Screening Program. CIMAR provides the digital infrastructure connecting DeepHealth’s AI lung solution across more than 90% of the program’s screening sites. The Program has demonstrated early success. UK Government data show that more than three-quarters (76%) of lung cancers detected through the program are now caught at earlier, more treatable stages compared to only 29% historically.¹

This stage shift highlights how connected, AI-powered screening programs can enable earlier disease detection, expand access to timely care and advance better patient outcomes. With this acquisition, DeepHealth aims to scale digitally enabled new and more efficient care models across the UK and Europe for other screening and diagnostic programs. The expansion would bring this connected healthcare model of image-based care programs to more patients and healthcare systems.

About RadNet
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 407 owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit http://www.radnet.com.

About DeepHealth
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in brain, breast, chest, prostate and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com/

Forward Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek, “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the anticipated benefits of the acquisition, the impact of the acquisition on RadNet’s business and future financial and operating results and prospects and the amount and timing of synergies from the acquisition are based on the current estimates, assumptions and projections of RadNet, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. None of RadNet, CIMAR or any of their respective directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the acquisition, which may be affected by, among other things, the ability of RadNet or CIMAR to maintain relationships with its vendors, customers, the NHS and providers and retain its management and key employees, (2) the ability of RadNet to achieve the synergies contemplated by the acquisition or such synergies taking longer to realize than expected, (3) costs related to the acquisition, (4) the ability of RadNet to execute successfully its strategic plans, (5) the ability of RadNet to promptly and effectively integrate CIMAR into its business, (6) the risk of litigation related to the acquisition, (7) the diversion of management’s time and attention from ordinary course business operations to integration matters, and (8) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

RadNet Contact
Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

Jane Mazur
Senior Vice President, Corporate Communications
+1 585-355-5978
jane.mazur@radnet.com

DeepHealth Contact
Andra Axente
Director of Communications
+31614440971
andra.axente@deephealth.com

References
      1)   Mouland, S. et al. “Targeted Lung Health Check Programme: Final evaluation report.” 2024.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f1132c9-5895-4441-a6e4-8e05e2633106

 

FAQ

What did RadNet (RDNT) announce on November 11, 2025 about CIMAR UK?

RadNet announced it acquired CIMAR UK and will integrate it into DeepHealth to expand AI-powered imaging and cloud-native image management.

How much of the NHS does CIMAR serve and what is the impact for RDNT (RDNT)?

CIMAR provides image infrastructure across more than 50% of NHS trusts and connects to >90% of NHS Lung Cancer Screening sites, increasing DeepHealth’s reach.

What clinical results support RadNet’s DeepHealth and CIMAR integration for RDNT (RDNT)?

UK government data cited a stage shift: 76% of lung cancers detected at earlier stages versus 29% historically in the screening program.

Will the CIMAR acquisition expand DeepHealth services across Europe for RDNT (RDNT)?

The announcement says DeepHealth aims to scale connected, image-based screening and diagnostic programs across the UK and Europe.

Did RadNet disclose the financial terms of the CIMAR acquisition (RDNT)?

The announcement does not disclose purchase price or specific financial terms.